and for targeted
therapy of age-associated pathologies, including malignant neoplasms. In this regard, the study
FEDOROVA, Y.Y.,
KARUNAS, A.S.,
GIMALOVA, G.F.,
KHUSNUTDINOVA, E.K.,
SAVELIEVA, O.N,
MURZINA, R.R.,
GATIYATULLIN, R.F.,
ETKINA, E.I. (2019) –60% of differences in sensitivity to
therapy in patients with BA is due to genetic variability. We studied